Acronnolife Genomics Private Limited
Strengthening testing quality for COVID-19 and other respiratory diseases
CURRENT IMPACT
As on May 2022
120,000
Sale of COVID-19 testing kits completed
Geographical Focus
- PAN India
Solution
- RT-LAMP-enabled COVID testing kits
Potential Impact
-
250,000
COVID tests to be conducted at subsidized rates
Agragesh Ramani Chief Executive Officer, Acrannolife Genomics Pvt. Ltd.
SAMRIDH is supporting us to create a sustainable model to achieve impact at scale. Through blended finance solutions, it has opened avenues for us to drive greater investments towards our expansion plans of Coviqwik. Complementing its financial support, SAMRIDH also provides us with domain knowledge and access to a vast network of experts, to improve our reach and uptake in the market.
Samridh support
SAMRIDH has enabled Acrannolife to launch and enhance the production and distribution capacity of their new product ‘CoviQwik’, an RT-LAMP enabled COVID-19 testing kit. With support from SAMRIDH, Accranolife will be conducting 250,000 tests at subsidized rates, out of which 170,000 will be utilized for the government hospitals and PM-JAY empanelled hospitals and diagnostic labs in Tier 1 and Tier 2 cities.
4 hours to 2 days
Currently, RT-PCR detection for COVID19 can take anywhere from 4 hours to 2 days
2 Billion
Of the 2 Billion COVID-19 cases reported in India, only ~800 million have been tested
Infectious and highly communicable diseases like COVID19 require mass and rapid testing to avoid the spread of the virus. While RT-PCR technology has been very effective in containing the COVID19 virus, it was also expensive and time consuming (approx. 4-6 hours). While Antigen tests are an alternative to this form of testing, they lack accuracy and have a high rate of false positives which can become a big problem in cases of emergencies like operations and surgical planning. This has created a need for point-of-care testing with affordable setup costs and lesser turnaround time.
Acrannolife aims to strengthen India’s diagnostic infrastructure through building solutions for early diagnosis and management of chronic conditions and infectious diseases. Acrannolife has developed “CoviQwik”, a Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) enabled technology which allows quicker analysis of genetic material than traditional RT-PCR tests. These tests maintain the accuracy of an RT-PCR but produce results within 45 minutes, they also cost 20% less than an RT-PCR test.
Key Stakeholders
